Last reviewed · How we verify
NCT06306976: ELASTOGRAPHY
Shear-Wave Elastography
NA trial testing Elective Midline Laparotomy in Ventral Incisional Hernia in 70 participants. Enrolling by invitation.
31 July 2026
Quick facts
| Lead sponsor | Prisma Health-Upstate |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 70 |
| Start date | 18 April 2024 |
| Primary completion | 31 July 2026 |
| Estimated completion | 31 August 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Elective Midline Laparotomy
- Imaging: Ultrasound
- Tensiometry
Conditions studied
- Ventral Incisional Hernia — all drugs for Ventral Incisional Hernia →
Sponsor
Prisma Health-Upstate — full company profile →
Who can join
18 and older, any sex, with Ventral Incisional Hernia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective cohort study of patients with midline ventral incisional hernia with a range of hernia morphology who plan to undergo open retromuscular VHR. Study groups: Study groups are selected across a range of morphology and based on factors known or suspected to affect the ability to achieve fascial closure. Control groups: The study plans to enlist 5 volunteers with no incisional hernia or prior laparotomy to establish internal baseline SWE values and interrater reliability. The study will also plan to recruit 5 patients undergoing primary laparotomy in order to correlate SWE findings with closure tension.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06306976
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Prisma Health-Upstate trials
Trials by the same sponsor.
- NCT07202039 — Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine · NA · not yet recruiting
- NCT07375212 — VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure · Phase 4 · withdrawn
- NCT07102615 — Intracervical Vasopressin · Phase 4 · recruiting
- NCT07101250 — Preoperative Acetazolamide · Phase 4 · recruiting
- NCT06874413 — Targeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Vent · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06306976 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prisma Health-Upstate
- Last refreshed: 6 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06306976.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing